Gossamer Bio and Chiesi sign deal for Seralutinib development
Under the deal, Gossamer Bio and Chiesi Group will develop and commercialise Seralutinib in PAH, PH-ILD & other…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 May 24
Under the deal, Gossamer Bio and Chiesi Group will develop and commercialise Seralutinib in PAH, PH-ILD & other…
07 May 24
For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a…
03 May 24
The partnership will combine Poseida Therapeutics’ allogeneic CAR-T platform with Xyphos Biosciences’ ACCEL technology to develop convertibleCAR programmes…
02 May 24
Poseida will combine its unique allogeneic CAR-T platform with Xyphos' ACCELTM technology to create one Poseida-developed CAR-T construct,…
02 May 24
As per the partnership, Nasdaq-listed Editas Medicine and Bristol Myers Squibb will research, develop, and market T cell…
02 May 24
Under the collaboration, the companies are developing antisense oligonucleotides (ASOs) for multiple neurodegenerative diseases
26 Apr 24
The collaboration will combine Regeneron's expertise in AAVs and antibodies with Mammoth's knowledge in compact gene editing to…
25 Apr 24
Moderna will embed OpenAI’s generative AI tools throughout its organisation and adopt ChatGPT Enterprise to use Generative AI…
23 Apr 24
Ipsen would acquire an exclusive global license to develop successful development candidates (DC), by paying up to $1.8bn…
23 Apr 24
The partnership agreement, which has the potential to earn more than $1bn for Ochre Bio, aims to discover…